Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MabionCD20 vs Rituximab in Rheumatoid Arthritis
NCT04680962Phase 3Withdrawn
- Sponsor
- Mabion S.A.
- Start
- Aug 2023
- Primary completion
- Aug 2023
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of MabionCD20 in rheumatoid arthritis (RA), sponsored by Mabion S.A.. Planned start Aug 2023; status: withdrawn.
02
Drugs
MabionCD20
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04680962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04680962.